Needham & Company LLC reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report report published on Tuesday,Benzinga reports. Needham & Company LLC currently has a $40.00 price target on the stock. Other analysts also recently issued research reports about the company. BTIG Research reaffirmed a “buy” rating […]

Needham & Company LLC restated their buy rating on shares of PAR Technology (NYSE:PAR – Free Report) in a report published on Monday,Benzinga reports. The brokerage currently has a $25.00 price objective on the software maker’s stock. Several other research firms also recently issued reports on PAR. JPMorgan Chase & Co. lifted their price target […]

Merit Medical Systems (NASDAQ:MMSI – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $101.00 target price on the medical instruments supplier’s stock. Needham & Company LLC’s price objective points to a potential […]

Needham & Company LLC restated their buy rating on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a research note published on Friday,Benzinga reports. They currently have a $110.00 price target on the stock. A number of other research analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares […]

Needham & Company LLC reaffirmed their buy rating on shares of Vicor (NASDAQ:VICR – Free Report) in a research note released on Tuesday, MarketBeat.com reports. They currently have a $320.00 price target on the electronics maker’s stock. VICR has been the subject of a number of other reports. Zacks Research lowered shares of Vicor from […]

Envista (NYSE:NVST – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & Company LLC in a research note issued to investors on Friday, Marketbeat.com reports. A number of other equities analysts have also commented on the stock. BMO Capital Markets restated a “market perform” rating on shares of Envista […]